Deep learning-based design and screening of benzimidazole-pyrazine derivatives as adenosine A receptor antagonists.

Journal: Journal of biomolecular structure & dynamics
PMID:

Abstract

The Adenosine A receptor (AAR) is considered a novel potential target for the immunotherapy of cancer, and AAR antagonists have an inhibitory effect on tumor growth, proliferation, and metastasis. In our previous studies, we identified a class of benzimidazole-pyrazine scaffolds whose derivatives exhibited the antagonistic effect but lacked subtype selectivity towards AAR. In this work, we developed a scaffold-based protocol that incorporates a deep generative model and multilayer virtual screening to design benzimidazole-pyrazine derivatives as potential selective AAR antagonists. By utilizing a generative model with reported AAR antagonists as the training set, we built up a scaffold-focused library of benzimidazole-pyrazine derivatives and processed a virtual screening protocol to discover potential AAR antagonists. Finally, five molecules with different Bemis-Murcko scaffolds were identified and exhibited higher binding free energies than the reference molecule 12o. Further computational analysis revealed that the 3-benzyl derivative ABA-1266 presented high selectivity toward AAR and showed preferred draggability, providing future potent development of selective AAR antagonists.

Authors

  • Rui Qin
    School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
  • Hao Zhang
    College of Mechanical and Electrical Engineering, Henan Agricultural University, Zhengzhou, 450002, China.
  • Weifeng Huang
    School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
  • Zhenglin Shao
    School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
  • Jinping Lei
    School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.